More detailed information about fatigue prevention can come once C2 59 45 76.2 treatment has started. What is your preferred format to receive educational material about C1 32 fatigue? Leaflet/printed material 19 59.4 Individual counselling 18 56.3 Group education sessions 10 31.3 Web Page 9 28.1 On-line interactive 3 9.4 DVD 1 3.1 Other 2 6.2 RESULTS: SURVEY 1 What are the five most important factors that would encourage you to adopt the CAPO CRF guideline? Agree Agree Statement Survey N (n) (%) HP#1 If the procedures are easily put into practice HP1 40 28 70.0 HP#2 Availability of staff educational materials or additional training in HP1 40 24 60.0 the guideline procedures HP#3 If service leaders, management or government endorsed the HP1 40 22 55.0 guideline HP#4 Availability of published evidence of the guideline's effectiveness HP1 40 20 42.5 HP#5 If forms, resources and referral pathways were available HP1 40 17 42.5 electronically CS#1 If my health professional promoted its use C1 32 24 75.0 CS#2 If service leaders, management or government endorsed the C1 32 23 71.9 guideline CS#3 Availability of health professionals with expertise to assess and C1 32 21 65.6 treat CRF CS#4 If it were endorsed by a leading Australian cancer organisation C1 32 18 56.2
More detailed information about fatigue prevention can come once treatment has started. C2 59 45 76.2 What is your preferred format to receive educational material about fatigue? Leaflet/printed material Individual counselling Group education sessions Web Page On-line interactive DVD Other C1 32 19 18 10 9 3 1 2 59.4 56.3 31.3 28.1 9.4 3.1 6.2 RESULTS: SURVEY 1 What are the five most important factors that would encourage you to adopt the CAPO CRF guideline? Statement Survey N Agree (n) Agree (%) HP#1 If the procedures are easily put into practice HP1 40 28 70.0 HP#2 Availability of staff educational materials or additional training in the guideline procedures HP1 40 24 60.0 HP#3 If service leaders, management or government endorsed the guideline HP1 40 22 55.0 HP#4 Availability of published evidence of the guideline's effectiveness HP1 40 20 42.5 HP#5 If forms, resources and referral pathways were available electronically HP1 40 17 42.5 CS#1 If my health professional promoted its use C1 32 24 75.0 CS#2 If service leaders, management or government endorsed the guideline C1 32 23 71.9 CS#3 Availability of health professionals with expertise to assess and treat CRF C1 32 21 65.6 CS#4 If it were endorsed by a leading Australian cancer organisation C1 32 18 56.2
12913_2017_2415_MOESM2_ESM.docx